Browse By Cell Line Result Page of OvirusTdb

The total number of records retrieved from this search are 3. Click on ID to see further detail.
IDOV_4413Virus nameAdenovirusVirus strainONYX-015Virus genome typeDNAVirus familyAdenoviridaeVirus genome modificationNoneVirus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineATCCOrigin of cell lineHuman colon carcinomaCell lineHT-29/carbo-15d-1Concentration of cell lineNAIn-vitro toxicityNAAssayStatistical methodIn-vitro virus concentration20.13+/- 10.23In-vitro result20% cancer cell deathModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedIncrease in apoptosis upto 25%Immunogenic effectNAClinical trialNAPMID26429639
IDOV_4414Virus nameAdenovirusVirus strainONYX-015Virus genome typeDNAVirus familyAdenoviridaeVirus genome modificationNoneVirus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineATCCOrigin of cell lineHuman colon carcinomaCell lineHT-29/carbo-15d-1Concentration of cell lineNAIn-vitro toxicityNAAssayStatistical methodIn-vitro virus concentration48.46+/- 19.03In-vitro result50% cancer cell deathModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedIncrease in apoptosis upto 25%Immunogenic effectNAClinical trialNAPMID26429639
IDOV_4415Virus nameAdenovirusVirus strainONYX-015Virus genome typeDNAVirus familyAdenoviridaeVirus genome modificationNoneVirus aloneYesVirus in combination with drug/radiationNoImmune gene insertion in viral genomeNoSource of cell lineATCCOrigin of cell lineHuman colon carcinomaCell lineHT-29/carbo-15d-1Concentration of cell lineNAIn-vitro toxicityNAAssayStatistical methodIn-vitro virus concentration78.27+/- 25.11In-vitro result70% cancer cell deathModel organismNoIn-vivo virus concentrationNoIn-vivo toxicityNA In-vivo resultNo responseMode of deliveryNAPathway inducedIncrease in apoptosis upto 25%Immunogenic effectNAClinical trialNAPMID26429639